| Submission declined on 23 June 2023 by BuySomeApples (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Please note we don't use external links in the body of an article. Theroadislong (talk) 17:55, 22 April 2023 (UTC)
Julian Avery Rees is an American inorganic chemist who specializes in the structure, properties, and behavior of metal atoms in biological systems. He is the co-founder, chief executive officer, and president of HOPO Therapeutics, a company that develops pharmaceutical chelating agents for the prevention and treatment of metal toxicity specifically from heavy metals.
Early life and education
editRees grew up in Seattle, Washington, and attended Garfield High School. He completed his undergraduate degree in chemistry at Goucher College in Baltimore, Maryland, before returning to Seattle and earning his M.S. (2013) and Ph.D. (2016) in inorganic chemistry at the University of Washington with Prof. Julie Kovacs.[1] During his graduate studies, Rees was a DAAD graduate scholar with Prof. Dr. Serena DeBeer at the Max Planck Institute for Chemical Energy Conversion in Mülheim a.d. Ruhr, Germany.[2][3] His graduate work focused on the structure-function relationship of transition metals in complex metalloenzyme clusters.[4][5][6]
Rees joined the group of Prof. Rebecca Abergel at Lawrence Berkeley National Laboratory (Berkeley Lab) for a postdoctoral fellowship, where he conducted research on the biochemistry of the actinide and lanthanide elements, chelating agents, and their applications in medicine.
Career
editAfter completing his postdoctoral fellowship, Rees and Abergel co-founded HOPO Therapeutics in 2020, a startup company spun out from Berkeley Lab and the University of California, Berkeley. The pair received a fellowship from the Bakar Fellows program, which supports translation of university research into products and applications, including through formation startup companies. HOPO Therapeutics is focused on developing treatments for a range of applications in heavy metal poisoning. Initially designed as a rapid intervention medical countermeasure against nuclear threats,[7] the company's lead drug candidate has also shown promise in treating exposure to gadolinium from MRI contrast agents[8] and lead poisoning.[9] As of 2022, it is in a Phase 1 clinical trial.[10]
Personal life
editRees is a musician, and sang in the Northwest Boychoir and Vocalpoint! Seattle while in grade school. He plays keyboard in Bay Area neo-classic rock band Bad Dog Jump.
References
edit- ^ "Group Members | Kovacs Research". 2023-04-17. Retrieved 2023-04-17.
- ^ "Prof. Dr. Serena DeBeer | MPI CEC". 2023-04-17. Retrieved 2023-04-17.
- ^ "Julian Rees, Ph.D. | HOPO Therapeutics". HOPO Therapeutics. 2023-04-17. Retrieved 2023-04-17.
- ^ Rees, Julian A.; Bjornsson, Ragnar; Kowalska, Joanna K.; Lima, Frederico A.; Schlesier, Julia; Sippel, Daniel; Weyhermüller, Thomas; Einsle, Oliver; Kovacs, Julie A.; DeBeer, Serena (2017). "Comparative electronic structures of nitrogenase FeMoco and FeVco". Dalton Transactions. 46 (8): 2445–2455. doi:10.1039/C7DT00128B. PMC 5322470. PMID 28154874. S2CID 434465.
- ^ Rees, Julian A.; Bjornsson, Ragnar; Schlesier, Julia; Sippel, Daniel; Einsle, Oliver; DeBeer, Serena (2015-11-02). "The Fe–V Cofactor of Vanadium Nitrogenase Contains an Interstitial Carbon Atom". Angewandte Chemie International Edition. 54 (45): 13249–13252. doi:10.1002/anie.201505930. ISSN 1433-7851. PMC 4675075. PMID 26376620.
- ^ Rees, Julian A.; Martin-Diaconescu, Vlad; Kovacs, Julie A.; DeBeer, Serena (2015-07-06). "X-ray Absorption and Emission Study of Dioxygen Activation by a Small-Molecule Manganese Complex". Inorganic Chemistry. 54 (13): 6410–6422. doi:10.1021/acs.inorgchem.5b00699. ISSN 0020-1669. PMC 4494871. PMID 26061165.
- ^ "A Single Dose for Good Measure: How an Anti-Nuclear-Contamination Pill Could Also Help MRI Patients". 2019-09-12. Retrieved 2023-04-22.
- ^ Rees, Julian A.; Deblonde, Gauthier J.-P.; An, Dahlia D.; Ansoborlo, Camille; Gauny, Stacey S.; Abergel, Rebecca J. (2018-03-13). "Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents". Scientific Reports. 8 (1): 4419. Bibcode:2018NatSR...8.4419R. doi:10.1038/s41598-018-22511-6. ISSN 2045-2322. PMC 5849765. PMID 29535330.
- ^ Deblonde, Gauthier J.-P.; Lohrey, Trevor D.; An, Dahlia D.; Abergel, Rebecca J. (2018-05-14). "Toxic heavy metal – Pb, Cd, Sn – complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-LI(1,2-HOPO)". New Journal of Chemistry. 42 (10): 7649–7658. doi:10.1039/C7NJ04559J. ISSN 1369-9261. OSTI 1458507. S2CID 67817360.
- ^ "Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics | ClinicalTrials.gov". 2022-11-29. Retrieved 2023-04-22.